Baseline covariates (%) | ABA | ADA | ETA | INF | LEF | MTX | RIT | SSZ-HCQ | Total |
---|---|---|---|---|---|---|---|---|---|
( N  =  27 ) | ( N  =  116 ) | ( N  =  113 ) | ( N  =  29 ) | ( N  =  110 ) | ( N  =  183 ) | ( N  =  24 ) | ( N  =  357 ) | ( N  =  959 ) | |
Unique patients | 25 | 113 | 112 | 26 | 98 | 170 | 18 | 302 | 566 |
Mean age, years (SD) | 60.5 (8.2) | 61.0 (9.9) | 61.2 (9.7) | 57.1 (9.4) | 64.5 (11.0) | 62.2 (10.6) | 62.2 (7.7) | 62.3 (10.5) | 62.1 (10.3) |
Male gender | 25 (92.6) | 106 (91.4) | 108 (95.6) | 23 (79.3) | 101 (91.8) | 167 (91.3) | 23 (95.8) | 327 (91.6) | 880 (91.8) |
Medication use six months prior start of treatment episode | Â | Â | Â | Â | |||||
MTX/LEF | 18 (66.7) | 71 (61.2) | 69 (61.1) | 20 (69.0) | 51 (46.4) | 17 (9.3) | 12 (50) | 145 (40.6) | 403 (42.0) |
HCQ/SSZ | 4 (14.8) | 18 (15.5) | 19 (16.8) | 4 (13.8) | 21 (19.1) | 68 (37.2) | 3 (12.5) | 45 (12.6) | 182 (19.0) |
Oral glucocorticoids | 9 (33.3) | 43 (37.1) | 50 (44.3) | 8 (27.6) | 39 (35.5) | 68 (37.2) | 13 (54.2) | 117 (32.8) | 347 (36.2) |
HBV antivirals1 | 1 (3.7) | 5 (4.3) | 2 (1.8) | 0 (0) | 0 (0) | 3 (1.6) | 0 (0) | 12 (3.4) | 23 (2.4) |
Comorbidities2 | Â | Â | Â | Â | Â | Â | Â | ||
Hepatitis C | 5 (18.5) | 18 (15.5) | 23 (20.4) | 7 (24.1) | 6 (5.5) | 11 (6.1) | 6 (25.0) | 69 (19.3) | 145 (15.1) |
COPD | 4 (14.8) | 13 (11.2) | 19 (16.8) | 8 (27.6) | 20 (18.2) | 5 (19.1) | 7 (29.2) | 65 (18.2) | 171 (17.8) |
Hypertension | 15 (55.6) | 65 (56.0) | 65 (57.5) | 14 (48.3) | 76 (69.1) | 112 (61.2) | 14 (58.3) | 236 (66.1) | 597 (62.3) |
Diabetes mellitus | 4 (14.8) | 22 (19.0) | 19 (16.8) | 2 (6.9) | 19 (17.3) | 50 (27.3) | 4 (16.7) | 90 (25.2) | 210 (21.9) |
Solid cancer | 2 (7.4) | 6 (5.2) | 5 (4.4) | 2 (6.9) | 17 (15.5) | 21 (11.5) | 2 (8.3) | 31 (8.7) | 86 (9.0) |